Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

What Becton Dickinson Brings to the Fight Against COVID-19

AI-generated analysis

🧬 Becton, Dickinson and Co. (BD) has launched a new point-of-care test to detect antibodies indicating current or past exposure to COVID-19.

⏱️ The assay delivers results in as little as 15 minutes without requiring special equipment, suitable for lab or point-of-care settings.

🀝 BD announced an agreement with BioMedomics to augment its rapid serology testing capabilities.

πŸ₯ The company is collaborating with Henry Schein to leverage the partner's extensive knowledge of the point-of-care test field.

πŸ“Š This new test helps clinicians identify asymptomatic infections and aids researchers in understanding true infection occurrence rates.

πŸ’° Becton Dickinson stock traded down less than 1% to $228.38, trading within a 52-week range of $197.75 to $286.72.

🎯 The consensus price target for Becton Dickinson is set at $270.62 by analysts.

πŸ”¬ BD's approach focuses on serology rather than just detecting the active novel coronavirus like some competitors.

Bullish Signals
  • BD has secured a strategic agreement with BioMedomics to integrate a rapid serology test, expanding its diagnostic capabilities in the high-demand COVID-19 testing market.
  • The new antibody detection test provides critical data on prior exposure, which is essential for public health strategies and understanding asymptomatic infection rates.
  • Collaboration with Henry Schein leverages a major distributor's expertise in point-of-care tests, potentially accelerating market adoption of BD's new assay.
Full Analysis
Becton, Dickinson and Co. (BD) has announced the release of a new point-of-care test designed to detect antibodies in blood, confirming current or past exposure to COVID-19. Unlike competitors focusing solely on detecting the active virus, BD's assay targets serology to identify immune responses, which is crucial for understanding infection rates among asymptomatic populations and informing future public health strategies. The new test can deliver results in as little as 15 minutes and does not require special equipment, making it suitable for use in laboratories or at the point of care. BD's Integrated Diagnostic Solutions division highlighted that this rapid serology test complements existing molecular diagnostics, helping clinicians rule out infection when combined with negative viral tests. To accelerate this effort, BD has entered into an agreement with BioMedomics to add a rapid serology test to its portfolio and is collaborating with Henry Schein, leveraging the latter's extensive knowledge of the point-of-care test field. This strategic move aims to provide additional data on prior exposure to SARS-CoV-2, aiding researchers in characterizing the true occurrence of the disease across the population. Financially, Becton Dickinson stock traded down less than 1% to $228.38 on Wednesday, maintaining a position within its 52-week range of $197.75 to $286.72. The consensus price target for the company stands at $270.62, while the article also provided context on competitor movements in the diagnostic testing sector.